SRR1797278
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.530
- ANDROGEN_RESPONSE+0.440
- MYC_TARGETS_V1+0.420
- MTORC1_SIGNALING+0.400
- PANCREAS_BETA_CELLS+0.390
- E2F_TARGETS+0.330
- INTERFERON_ALPHA_RESPONSE+0.330
- INTERFERON_GAMMA_RESPONSE+0.320
- MITOTIC_SPINDLE+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.320
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.350
- HEDGEHOG_SIGNALING-0.340
- NOTCH_SIGNALING-0.290
- ANGIOGENESIS-0.270
- TGF_BETA_SIGNALING-0.250
- COAGULATION-0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
- KRAS_SIGNALING_DN-0.180
- MYOGENESIS-0.160
- UV_RESPONSE_DN-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A202-01A-11R-A14M-07 | — | C | 0.844 |
| 2 | SRR29022835 | — | C | 0.815 |
| 3 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.812 |
| 4 | R328 | — | — | 0.804 |
| 5 | SRR6013495 | — | cohortA1 | 0.803 |
| 6 | faffc96a-760c-405c-9bec-d2ec116b4a1d | — | — | 0.801 |
| 7 | TCGA-A8-A09I-01A-22R-A034-07 | — | C | 0.799 |
| 8 | C3L-04757 | — | cohortA1 | 0.796 |
| 9 | DRR168535 | — | — | 0.794 |
| 10 | f9c74189-6bdc-49b9-b984-917ffe2b097d | — | — | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.530 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |